NYRADA INC. (ASX:NYR) 46 Assessment of R&D expenditure not advancing to a stage of technical feasibility Research costs are expensed in the period in which they are incurred. Development costs are capitalised when it is probable that the project will be a success considering its commercial and technical feasibility; the Consolidated Entity is able to use or sell the asset; the Consolidated Entity has sufficient resources and intent to complete the development; and its costs can be measured reliably. 4. Operating segments Consistent with FY25 financial year, the Board considers that the Consolidated Entity has only operated in one Segment being research and development of drugs focusing on small molecules with potential therapeutic benefit in areas of significant medical need and it operates in one geographical area being Australasia. The financial information presented in the statement of financial performance and statement of financial position represents the information for the business segment. 5. Other income 2026 2025 $ $ Interest received 182,147 162,069 6. Research and development grant income 2026 2025 $ $ Research and development grant income 2,011,340 2,396,734 The estimated FY2026 research and development tax incentive refund is $1,720,573. In FY2026, the Company received a research and development tax incentive refund greater than the amount accrued of $290,766 for the period ending 30 June 2025. 7. Trade, other receivables and prepayments 2026 2025 $ $ Current assets Research and development tax incentive receivable 1,720,573 2,155,853 Prepayments 204,630 55,202 Other receivables 75,206 129,441 2,000,409 2,340,496 8. Trade and other payables 2026 2025 $ $ Current liabilities Trade payables 193,403 908,628 Accrued expenses 291,235 443,777 Amounts owing to related party: key management personnel (see note 19) 75,603 102,538 Other payables 30,021 26,807 590,262 1,481,750
RkJQdWJsaXNoZXIy MjE2NDg3